Integra LifeSciences Holdings Corporation recently announced several changes to the leadership of its Orthopedics and Tissue Technologies business.
“This new combined organization will allow us to deploy our best people across our product development teams; enable common approaches in areas such as marketing, product launches, sourcing and kitting; and provide new organic growth opportunities,” Mark Augusti, corporate vice president and president of Orthopedics and Tissue Technologies for Integra said in a company press release.
Newly appointed leaders from marketing for the division and strategy for advanced wound care, orthopedics product development, quality and regulatory, U.S. extremities sales, and U.S. spine and orthobiologic sales will report to Augusti directly.
In light of the reorganization, Integra will be able to more efficiently utilize resources, maximizing the company’s existing channels while developing new ones and launching new products more effectively, according to the press release.
During the short-term, the company expects to invest expense reductions from the new organization into product development and sales efforts, according to the release.